Building a new standard for biosimilars
Valorum is creating a new blueprint for biosimilar adoption that aligns value, trust, and autonomy, leading to lasting stability for practices, partners, and patients.
Dependable access.
Clearer value.
Less disruption.
In today’s biosimilar landscape, many physicians face a process that is difficult to navigate—one fraught with instability and commoditization that undermines clinical autonomy.
Valorum sees a different path forward. We are deeply committed to understanding and addressing the real needs of physicians—building our business in markets where clinicians have the authority to make the right decisions for their patients, restoring balance and long-term sustainability to the biosimilar model.
We listened to practices and designed our approach with their day-to-day realities in mind. Our goal is to give control back to practices and reduce both financial and operational burden, creating a model that finally works for those delivering care.
We are defining a new standard, one that creates lasting stability for practices, partners, and patients.
Dependable Access
Long-term commercialization strategies designed to support supply continuity and provider confidence so practices can plan ahead, not react constantly
Clearer Value
Disciplined pricing and predictability that cut through volatility, giving providers the clarity to make confident decisions
Less Disruption
Partnership models built around buy-and-bill realities and specialty care delivery, reducing operational burden and administrative churn
Strategic pipeline designed to deliver sustainable care
We actively seek and address overlooked gaps—championing both foundational and underserved markets—so more patients and practices benefit from dependable access and enduring value. We see opportunities to build biosimilar care for the long-term, ensuring success across a range of therapeutic areas and practice settings, with an initial focus on oncology and ophthalmology.
Proven expertise. Built to execute.
At Valorum, our leadership team is guided by a deep commitment to people—patients, providers, and partners—who deserve better from biosimilars. Our team brings together decades of real-world experience in oncology, community specialty practice, and patient access, with a proven track record across some of the industry’s most respected organizations, including McKesson, Cencora, and Cardinal Health. More than a group of experts, we’re united by a shared purpose: to make biosimilar access truly work for those who need it most. Every day, we bring clarity, dependability, and strategic thinking to a complex market because we know what it takes to make a lasting difference.
Setting a higher bar for patients, practices, and progress
At Valorum, we believe in the power of engineering access through real-world biosimilar know-how, disciplined pricing, and market agility—giving providers back control and making stability the new standard. We’re leveraging our deep biosimilar expertise to help create a more seamless human experience for the people who rely on care.
If you want your work to make a meaningful difference, we’d love to hear from you.
Get in touch
If you want to learn more about Valorum or are interested in partnering opportunities, please reach out.
555 Madison Avenue, Suite 11D
New York, NY 10022
